Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 August 2020 | Story Leonie Bolleurs | Photo Charl Devenish
Poojah Jawallapersand strives for academic excellence and to empower others through research and innovation.

As South Africa commemorates Women’s Day on 9 August 2020 and continues Women’s Month celebrations throughout August, the UFS shines a spotlight on women who are making an impact on our three campuses on a daily basis.

One of these women is Poojah Jawallapersand, a PhD student majoring in Biochemistry. Poojah is part of the Pathogenic Yeast Research Group in the Department of Microbial, Biochemical and Food Biotechnology. 

In her current research study, she is investigating whether fungal yeast cells and components from the opportunistic and fungal pathogen Candida albicans can cause Alzheimer’s disease-like symptoms, and if these symptoms can be effectively treated through drug repositioning. The study is being conducted on zebrafish larvae.

Jawallapersand explains that drug repositioning is a drug development strategy that involves finding alternative indications for existing licensed drugs for novel therapeutic purposes. “In short, the use of old drugs for new uses. There is no cure for Alzheimer’s disease, hence this research will pave the way towards identifying effective treatment options to treat the disease,” she says. 

“Be confident and dare to be yourself because you are worth more than you think.” - Poojah Jawallapersand

An interview with Jawallapersand reveals more about the woman behind this much-needed research study. 

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

“My mother and Mrs Deeya Domah (my high-school teacher) constantly inspire me and have played a pivotal role in my life. My mother taught me the value of life, encouraged me to embrace my cultural heritage and spirituality, and always urged me to be ‘original’.”

“As a teenager, Mrs Domah introduced me and made me fall in love with the study of life (biology), to the extent that I made a career out of it. She inspired me through her timeless elegance and passion for teaching and learning, her willingness to go the extra mile in helping her students, her role in environmental and ecological sustainability, her support towards the empowerment of women, and her influence as an educator and role model in the lives of numerous individuals.”

What are some challenges you have faced in your life that have made you a better woman?

“Although I have experienced several challenges in my life, the greatest challenge for me is still to master my mind and emotions. It is vital to have a strong support system to overcome these challenges; for me, this has always been my faith, my parents, and my sister. I am glad that I have gone through these trials; they taught me how to deal with some issues, to stay enthusiastic, to appreciate myself, to practice self-love, and to master the art of constantly picking myself up when I fall. I am still a work in progress and strive daily for self-improvement. However, I have become stronger, more resilient, and a better woman because of these challenges.”

What advice would you give to the 15-year-old you?

“Enjoy your adolescence, have fun, make memories, live these moments, and do not rush into adulthood. Stop trying to please other people and learn to say ‘no’. Be confident and dare to be yourself because you are worth more than you think.”

What would you say makes you a champion woman [of the UFS]?

“I am a champion woman of the UFS; I embrace my uniqueness, and I strive for academic excellence and to empower others through research and innovation. I say no to discrimination, no to gender-based violence, and no to gender inequality. I am generation equality, and this is my legacy.”

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept